• Explore /
  • Poster
  • / A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Abstract Poster

Authors

null

Daisuke Kotani

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Daisuke Kotani , Kensei Yamaguchi , Ken Kato , Hiroki Hara , Akinori Miura , Taroh Satoh , Keigo Komine , Chikara Kunisaki , Hiroshi Yabusaki , Akiko Hagiwara , Noriko Suzuki , Kiichiro Toyoizumi , Joshua C Curtin , Sanjib Chowdhury , Roland Elmar Knoblauch , Toshihiko Doi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04945733

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 363)

DOI

10.1200/JCO.2024.42.3_suppl.363

Abstract #

363

Poster Bd #

H5

Abstract Disclosures

Similar Posters

First Author: Xiangrui Meng

First Author: Xiaojing Xu

First Author: Xiaojing Xu

First Author: Tony S. K. Mok